Department of Pediatrics

Education

• BS, Highest Honors, The University of Michigan, 1979
• MS, The University of Michigan, 1980
• MD, With Distinction, The University of Michigan Medical School, 1986
• PhD, The University of Michigan, 1984

Training

• Internship, The Hospital of The University of Pennsylvania, 1986 - 1987
• Residency, The Hospital of The University of Pennsylvania, 1987 - 1990
• Postdoctoral Fellowship, The University of Michigan Medical Center, 1990 - 1993

Licensure and Board Certification

• PA, Medical License, 1986
• MI, Medical License, 1990
• Neurology Board Certification, 1992 - Pres
• MO, Medical License, 1993 - Pres

Honors

• Gordon-Timmis Research Fellowship, 1977
• Michigan Alumni-Regents Scholarship, 1977
• Henry Ford Hospital Research Fellowship, 1978
• Campbell Cancer Research Fellowship, 1980
• March of Dimes Thomas Francis, Jr. Award, 1980
• Campbell Cancer Research Fellowship, 1981
• Campbell Cancer Research Fellowship, 1982
• Horace H. Rackham PreDoctoral Fellowship, 1982
• Campbell Cancer Research Fellowship, 1983
• Horace H. Rackham PreDoctoral Fellowship, 1983
• NIH Clinical Investigator Development Award (K08), NINDS, 1992
• March of Dimes Young Investigator Award, FASEB Summer, 1993
• Peter A. Aron National Neurofibromatosis Foundation Award, 1994
• Decade of the Brain Plenary Session Speaker, American Academy of Neurology, 1996
• American Neurological Association, elected member, 1997
• Carolyn Farb Endowed Lecture in Neurofibromatosis, 1998
• National Neurofibromatosis Foundation Crystal Award, 1998
• Eliason Teaching Award, Department of Neurology, 1999
• Fellow, American Neurological Association, 1999
• Walker Lecturer in Neurofibromatosis, 1999
• Linse Block Neuro-oncology Visiting Professor, Mayo Clinic Foundation, 2001
• Donald O. Schnuck Family (Endowed) Chair in Neurology, 2002
• National Neurofibromatosis Foundation Center of Excellence Award, 2002
• American Society for Clinical Investigation Induction, 2003
• Washington University School of Medicine Clinical Teacher of the Year Award, 2003
• Manuel R. Gomez Named Visiting Professor, 2006
• Award for Excellence in Pediatric Basic/Translational Research, Society for Neuro-Oncology, 2007
• Ninth Annual Arthur and Sonia Labatt Brain Tumor Research Centre Lecturer, 2007
• Award for Excellence in Pediatric Translational Research, Society for Neuro-Oncology, 2008
• Takao Hoshino Lectureship, University of California – San Francisco, 2008
• Pfizer Visiting Professor, University of Virginia, 2010
• Ranked in top 10% of Barnes-Jewish Hospital Physician Providers (Patient Satisfaction), 2010
• University of Arkansas MD/PhD Student Choice Speaker, 2010
• Washington University/Siteman Cancer Center “Rock Doc”, 2010
• Children’s Tumor Foundation Frederich Von Recklinghausen (Lifetime Achievement) Award, 2012
• 16th Annual Sara Hertafeld Memorial Lectureship, 2013
• Susan B. Stine Memorial Lectureship, 2013
• Washington University Distinguished Faculty Research Award, 2013
• 8th Annual Riley Church Guest Professor, Stanford University, 2014
• Oregon Society for Neuroscience Retreat Keynote speaker, 2015
• Alexander von Humboldt Research Award, 2017
• Berlin Institute of Health Einstein Visiting Fellowship, 2017 - Pres
• Elected Fellow, American Academy of Neurology (AAN), 2018
• Abjihit Guha Award and Lecture, 2019

Recent Publications view all (438)

Publication Co-Authors

Manu S. Goyal

Todd Druley, M.D., Ph.D.

Nicole Brossier

Steven Mennerick

Joshua B. Rubin, M.D., Ph.D.

Allison King, M.D., M.P.H., Ph.D.

Todd N. Wylie

Abby Hollander, M.D.

Washington University has a long tradition of collaboration amongst colleagues.The faculty above have co-authored publications with David H. Gutmann, MD, PhD, FAAN

1. Haage V, Semtner M, Vidal RO, Hernandez DP, Pong WW, Chen Z, Hambardzumyan D, Magrini V, Ly A, Walker J, Mardis E, Mertins P, Sauer S, Kettenmann H, Gutmann DH. Comprehensive gene expression meta-analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma. Acta Neuropathol Commun. 2019;7(1):20. PMCID:PMC6376799  PMID:30764877 
2. Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ. Challenges to curing primary brain tumours. Nat Rev Clin Oncol. 2019. PMID:30733593 
3. Eby NS, Griffith JL, Gutmann DH, Morris SM. Adaptive functioning in children with neurofibromatosis type 1: relationship to cognition, behavior, and magnetic resonance imaging. Dev Med Child Neurol. 2019. PMID:30659594 
4. Anastasaki C, Rensing N, Johnson KJ, Wong M, Gutmann DH. Neurofibromatosis type 1 (Nf1)-mutant mice exhibit increased sleep fragmentation. J Sleep Res. 2019;e12816. PMID:30609083 
5. Chen R, Keoni C, Waker CA, Lober RM, Gutmann DH, Chen YH. KIAA1549-BRAF Expression Establishes a Permissive Tumor Microenvironment Through NFκB-Mediated CCL2 Production. Neoplasia. 2019;21(1):52-60. PMCID:PMC6277251  PMID:30504064 
6. Freret ME, Gutmann DH. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1. J Neurosci Res. 2019;97(1):45-56. PMID:29704429 
7. Durón C, Pan Y, Gutmann DH, Hardin J, Radunskaya A. Variability of Betweenness Centrality and Its Effect on Identifying Essential Genes. Bull Math Biol. 2018. PMID:30350013 
8. Isakson SH, Rizzardi AE, Coutts AW, Carlson DF, Kirstein MN, Fisher J, Vitte J, Williams KB, Pluhar GE, Dahiya S, Widemann BC, Dombi E, Rizvi T, Ratner N, Messiaen L, Stemmer-Rachamimov AO, Fahrenkrug SC, Gutmann DH, Giovannini M, Moertel CL, Largaespada DA, Watson AL. Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Commun Biol. 2018;1:158. PMCID:PMC6168575  PMID:30302402 
9. Zessis NR, Gao F, Vadlamudi G, Gutmann DH, Hollander AS. Height Growth Impairment in Children With Neurofibromatosis Type 1 Is Characterized by Decreased Pubertal Growth Velocity in Both Sexes. J Child Neurol. 2018;33(12):762-766. PMID:30009646 
10. Griffith JL, Morris SM, Mahdi J, Goyal MS, Hershey T, Gutmann DH. Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1. Neurol Clin Pract. 2018;8(4):283-291. PMCID:PMC6105062  PMID:30140579 
11. Freret ME, Anastasaki C, Gutmann DH. Independent NF1 mutations underlie café-au-lait macule development in a woman with segmental NF1. Neurol Genet. 2018;4(4):e261. PMCID:PMC6066364  PMID:30065955 
12. Pan Y, Duron C, Bush EC, Ma Y, Sims PA, Gutmann DH, Radunskaya A, Hardin J. Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma. PLoS One. 2018;13(5):e0190001. PMCID:PMC5963759  PMID:29787563 
13. Hirbe AC, Zhang X, Dahiya S, Godec A, Chrisinger J, Tao Y, Luo J, Gutmann DH. β-III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors. Neuro Oncol. 2018;20(6):858-860. PMCID:PMC5961120  PMID:29596596 
14. Pan Y, Xiong M, Chen R, Ma Y, Corman C, Maricos M, Kindler U, Semtner M, Chen YH, Dahiya S, Gutmann DH. Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth. Genes Dev. 2018;32(7-8):491-496. PMCID:PMC5959233  PMID:29632086 
15. Bai L, Lee Y, Hsu CT, Williams JA, Cavanaugh D, Zheng X, Stein C, Haynes P, Wang H, Gutmann DH, Sehgal A. A Conserved Circadian Function for the Neurofibromatosis 1 Gene. Cell Rep. 2018;22(13):3416-3426. PMCID:PMC5898822  PMID:29590612 
16. Khatua S, Gutmann DH, Packer RJ. Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights. Pediatr Blood Cancer. 2018;65(3). PMID:29049847 
17. Morris SM, Gutmann DH. A genotype-phenotype correlation for quantitative autistic trait burden in neurofibromatosis 1. Neurology. 2018;90(8):377-379. PMID:29367450 
18. Wegscheid ML, Anastasaki C, Gutmann DH. Human stem cell modeling in neurofibromatosis type 1 (NF1). Exp Neurol. 2018;299(Pt B):270-280. PMCID:PMC5630478  PMID:28392281 
19. Maloney SE, Chandler KC, Anastasaki C, Rieger MA, Gutmann DH, Dougherty JD. Characterization of early communicative behavior in mouse models of neurofibromatosis type 1. Autism Res. 2018;11(1):44-58. PMCID:PMC5773379  PMID:28842941 
20. Woodford MR, Sager RA, Marris E, Dunn DM, Blanden AR, Murphy RL, Rensing N, Shapiro O, Panaretou B, Prodromou C, Loh SN, Gutmann DH, Bourboulia D, Bratslavsky G, Wong M, Mollapour M. Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients. EMBO J. 2017;36(24):3650-3665. PMCID:PMC5730846  PMID:29127155 
21. Zou J, Zhang B, Gutmann DH, Wong M. Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age-dependent manner. Epilepsia. 2017;58(12):2053-2063. PMCID:PMC5716871  PMID:29023667 
22. Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca., Cancer Genome Atlas Research Network.. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell. 2017;171(4):950-965.e28. PMCID:PMC5693358  PMID:29100075 
23. Vogel AC, Gutmann DH, Morris SM. Neurodevelopmental disorders in children with neurofibromatosis type 1. Dev Med Child Neurol. 2017;59(11):1112-1116. PMID:28845518 
24. Anastasaki C, Morris SM, Gao F, Gutmann DH. Children with 5'-end NF1 gene mutations are more likely to have glioma. Neurol Genet. 2017;3(5):e192. PMCID:PMC5610042  PMID:28955729 
25. de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, Avery RA. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. J Neuroophthalmol. 2017;37 Suppl 1:S23-S32. PMID:28806346 
26. Pan Y, Bush EC, Toonen JA, Ma Y, Solga AC, Sims PA, Gutmann DH. Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN/PI3K-regulated glioma transcriptional signature. Oncotarget. 2017;8(32):52474-52487. PMCID:PMC5581044  PMID:28881745 
27. Reilly KM, Kim A, Blakely J, Ferner RE, Gutmann DH, Legius E, Miettinen MM, Randall RL, Ratner N, Jumbé NL, Bakker A, Viskochil D, Widemann BC, Stewart DR. Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. J Natl Cancer Inst. 2017;109(8). PMCID:PMC6057517  PMID:29117388 
28. Anastasaki C, Le LQ, Kesterson RA, Gutmann DH. Updated nomenclature for human and mouse neurofibromatosis type 1 genes. Neurol Genet. 2017;3(4):e169. PMCID:PMC5530422  PMID:28804759 
29. Campian J, Gutmann DH. CNS Tumors in Neurofibromatosis. J Clin Oncol. 2017;35(21):2378-2385. PMCID:PMC5516481  PMID:28640700 
30. Solga AC, Toonen JA, Pan Y, Cimino PJ, Ma Y, Castillon GA, Gianino SM, Ellisman MH, Lee DY, Gutmann DH. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. Oncotarget. 2017;8(29):47206-47215. PMCID:PMC5564557  PMID:28525381 
31. Anastasaki C, Dahiya S, Gutmann DH. KIR2DL5 mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth. Oncotarget. 2017;8(29):47574-47585. PMCID:PMC5564588  PMID:28548933 
32. Toonen JA, Ma Y, Gutmann DH. Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction. Neuro Oncol. 2017;19(6):808-819. PMCID:PMC5464459  PMID:28039362 
33. Blakeley JO, Bakker A, Barker A, Clapp W, Ferner R, Fisher MJ, Giovannini M, Gutmann DH, Karajannis MA, Kissil JL, Legius E, Lloyd AC, Packer RJ, Ramesh V, Riccardi VM, Stevenson DA, Ullrich NJ, Upadhyaya M, Stemmer-Rachamimov A. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis. Am J Med Genet A. 2017;173(6):1714-1721. PMID:28436162 
34. Hoye ML, Koval ED, Wegener AJ, Hyman TS, Yang C, O'Brien DR, Miller RL, Cole T, Schoch KM, Shen T, Kunikata T, Richard JP, Gutmann DH, Maragakis NJ, Kordasiewicz HB, Dougherty JD, Miller TM. MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models. J Neurosci. 2017;37(22):5574-5586. PMCID:PMC5452343  PMID:28416596 
35. Pan Y, Smithson LJ, Ma Y, Hambardzumyan D, Gutmann DH. Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival. Oncotarget. 2017;8(20):32977-32989. PMCID:PMC5464843  PMID:28380429 
36. Chen Z, Feng X, Herting CJ, Garcia VA, Nie K, Pong WW, Rasmussen R, Dwivedi B, Seby S, Wolf SA, Gutmann DH, Hambardzumyan D. Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. Cancer Res. 2017;77(9):2266-2278. PMCID:PMC5741820  PMID:28235764 
37. Camargo N, Goudriaan A, van Deijk AF, Otte WM, Brouwers JF, Lodder H, Gutmann DH, Nave KA, Dijkhuizen RM, Mansvelder HD, Chrast R, Smit AB, Verheijen MHG. Oligodendroglial myelination requires astrocyte-derived lipids. PLoS Biol. 2017;15(5):e1002605. PMCID:PMC5446120  PMID:28549068 
38. Walter C, Crawford L, Lai M, Toonen JA, Pan Y, Sakiyama-Elbert S, Gutmann DH, Pathak A. Increased Tissue Stiffness in Tumors from Mice with Neurofibromatosis-1 Optic Glioma. Biophys J. 2017;112(8):1535-1538. PMCID:PMC5406378  PMID:28445745 
39. Mahdi J, Shah AC, Sato A, Morris SM, McKinstry RC, Listernick R, Packer RJ, Fisher MJ, Gutmann DH. A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. Neurology. 2017;88(16):1584-1589. PMCID:PMC5395076  PMID:28330960 
40. Hirbe AC, Kaushal M, Sharma MK, Dahiya S, Pekmezci M, Perry A, Gutmann DH. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Cancer. 2017;123(7):1194-1201. PMID:27875628 
41. Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004. PMID:28230061 
42. Ishii T, Ueyama T, Shigyo M, Kohta M, Kondoh T, Kuboyama T, Uebi T, Hamada T, Gutmann DH, Aiba A, Kohmura E, Tohda C, Saito N. A Novel Rac1-GSPT1 Signaling Pathway Controls Astrogliosis Following Central Nervous System Injury. J Biol Chem. 2017;292(4):1240-1250. PMCID:PMC5270470  PMID:27941025 
43. Toonen JA, Solga AC, Ma Y, Gutmann DH. Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology. J Exp Med. 2017;214(1):17-25. PMCID:PMC5206494  PMID:27923908 
44. Hirbe AC, Gutmann DH. The management of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors: Challenges, progress, and future prospects. Expert Opinion on Orphan Drugs. 2017;5:623-631. 
45. Ricker CA, Pan Y, Gutmann DH, Keller C. Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma. Front Oncol. 2016;6:259. PMCID:PMC5167692  PMID:28066715 
46. Payne JM, Barton B, Ullrich NJ, Cantor A, Hearps SJ, Cutter G, Rosser T, Walsh KS, Gioia GA, Wolters PL, Tonsgard J, Schorry E, Viskochil D, Klesse L, Fisher M, Gutmann DH, Silva AJ, Hunter SJ, Rey-Casserly C, Cantor NL, Byars AW, Stavinoha PL, Ackerson JD, Armstrong CL, Isenberg J, O'Neil SH, Packer RJ, Korf B, Acosta MT, North KN, NF Clinical Trials Consortium.. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016;87(24):2575-2584. PMCID:PMC5207004  PMID:27956565 
47. Morris SM, Acosta MT, Garg S, Green J, Huson S, Legius E, North KN, Payne JM, Plasschaert E, Frazier TW, Weiss LA, Zhang Y, Gutmann DH, Constantino JN. Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT). JAMA Psychiatry. 2016;73(12):1276-1284. PMCID:PMC5298203  PMID:27760236 
48. Morris SM, Monroe CL, Gutmann DH. Macrocephaly Is Not a Predictor of Optic Pathway Glioma Development or Treatment in Neurofibromatosis Type 1. J Child Neurol. 2016;31(14):1540-1545. PMID:27581847 
49. Anderson DM, Van de Plas R, Rose KL, Hill S, Schey KL, Solga AC, Gutmann DH, Caprioli RM. 3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma. J Proteomics. 2016;149:77-84. PMCID:PMC4983271  PMID:26883872 
50. Smithson LJ, Anastasaki C, Chen R, Toonen JA, Williams SB, Gutmann DH. Contextual signaling in cancer. Semin Cell Dev Biol. 2016;58:118-26. PMCID:PMC5028257  PMID:27269372 
51. Schwetye KE, Joseph NM, Al-Kateb H, Rich KM, Schmidt RE, Perry A, Gutmann DH, Dahiya S. Gliosarcomas lack BRAF^V600E mutation, but a subset exhibit β-catenin nuclear localization. Neuropathology. 2016;36(5):448-455. PMID:26932501 
52. Gutmann DH. Exploring the genetic basis for clinical variation in neurofibromatosis type 1. Expert Rev Neurother. 2016;16(9):999-1001. PMCID:PMC4998178  PMID:27171602 
53. Plotkin SR, Davis SD, Robertson KA, Akshintala S, Allen J, Fisher MJ, Blakeley JO, Widemann BC, Ferner RE, Marcus CL, REiNS International Collaboration.. Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1. Neurology. 2016;87(7 Suppl 1):S13-20. PMCID:PMC5578358  PMID:27527645 
54. Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P, Plotkin SR, REiNS International Collaboration.. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology. 2016;87(7 Suppl 1):S40-8. PMCID:PMC5578360  PMID:27527649 
55. Walsh KS, Janusz J, Wolters PL, Martin S, Klein-Tasman BP, Toledo-Tamula MA, Thompson HL, Payne JM, Hardy KK, de Blank P, Semerjian C, Gray LS, Solomon SE, Ullrich N, REiNS International Collaboration.. Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention. Neurology. 2016;87(7 Suppl 1):S21-30. PMCID:PMC5578356  PMID:27527646 
56. Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, Farschtschi S, Jacobs MA, Chhabra A, Salamon JM, Wenzel R, Mautner VF, Dombi E, Cai W, Plotkin SR, Blakeley JO, Whole Body MRI Committee for the REiNS International Collaboration., REiNS International Collaboration Members 2016.. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology. 2016;87(7 Suppl 1):S31-9. PMCID:PMC5578359  PMID:27527647 
57. Wolters PL, Martin S, Merker VL, Tonsgard JH, Solomon SE, Baldwin A, Bergner AL, Walsh K, Thompson HL, Gardner KL, Hingtgen CM, Schorry E, Dudley WN, Franklin B, REiNS International Collaboration.. Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. Neurology. 2016;87(7 Suppl 1):S4-S12. PMCID:PMC5578357  PMID:27527648 
58. Li K, Turner AN, Chen M, Brosius SN, Schoeb TR, Messiaen LM, Bedwell DM, Zinn KR, Anastasaki C, Gutmann DH, Korf BR, Kesterson RA. Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I. Dis Model Mech. 2016;9(7):759-67. PMCID:PMC4958313  PMID:27482814 
59. Smithson LJ, Gutmann DH. Proteomic analysis reveals GIT1 as a novel mTOR complex component critical for mediating astrocyte survival. Genes Dev. 2016;30(12):1383-8. PMCID:PMC4926861  PMID:27340174 
60. Baker SJ, Ellison DW, Gutmann DH. Pediatric gliomas as neurodevelopmental disorders. Glia. 2016;64(6):879-95. PMCID:PMC4833573  PMID:26638183 
61. Johnson KJ, Zoellner NL, Gutmann DH. Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1. Cancer Epidemiol. 2016;42:53-9. PMCID:PMC4899111  PMID:27018750 
62. Toonen JA, Anastasaki C, Smithson LJ, Gianino SM, Li K, Kesterson RA, Gutmann DH. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1. Hum Mol Genet. 2016;25(9):1703-13. PMCID:PMC4986327  PMID:26908603 
63. Chen YH, Cimino PJ, Luo J, Dahiya S, Gutmann DH. ABCG1 maintains high-grade glioma survival in vitro and in vivo. Oncotarget. 2016;7(17):23416-24. PMCID:PMC5029636  PMID:26981778 
64. Porcelli B, Zoellner NL, Abadin SS, Gutmann DH, Johnson KJ. Associations between allergic conditions and pediatric brain tumors in Neurofibromatosis type 1. Fam Cancer. 2016;15(2):301-8. PMCID:PMC5080205  PMID:26666764 
65. Zafar R, Hsiao EY, Botteron KN, McKinstry RC, Gutmann DH. De novo development of gliomas in a child with neurofibromatosis type 1, fragile X and previously normal brain magnetic resonance imaging. Radiol Case Rep. 2016;11(1):33-5. PMCID:PMC4769616  PMID:26973730 
66. Hirbe AC, Dahiya S, Friedmann-Morvinski D, Verma IM, Clapp DW, Gutmann DH. Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation. Oncotarget. 2016;7(7):7403-14. PMCID:PMC4884927  PMID:26859681 
67. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, TCGA Research Network., Noushmehr H, Iavarone A, Verhaak RG. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016;164(3):550-63. PMCID:PMC4754110  PMID:26824661 
68. Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2016;19(1):20-7. PMCID:PMC4876023  PMID:26713745 
69. Omrani A, van der Vaart T, Mientjes E, van Woerden GM, Hojjati MR, Li KW, Gutmann DH, Levelt CN, Smit AB, Silva AJ, Kushner SA, Elgersma Y. HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. Mol Psychiatry. 2015;20(11):1311-21. PMCID:PMC5603719  PMID:25917366 
70. Solga AC, Pong WW, Kim KY, Cimino PJ, Toonen JA, Walker J, Wylie T, Magrini V, Griffith M, Griffith OL, Ly A, Ellisman MH, Mardis ER, Gutmann DH. RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth. Neoplasia. 2015;17(10):776-88. PMCID:PMC4656811  PMID:26585233 
71. Hirbe AC, Dahiya S, Miller CA, Li T, Fulton RS, Zhang X, McDonald S, DeSchryver K, Duncavage EJ, Walrath J, Reilly KM, Abel HJ, Pekmezci M, Perry A, Ley TJ, Gutmann DH. Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma. Clin Cancer Res. 2015;21(18):4201-11. PMCID:PMC4573781  PMID:25925892 
72. Constantino JN, Zhang Y, Holzhauer K, Sant S, Long K, Vallorani A, Malik L, Gutmann DH. Distribution and Within-Family Specificity of Quantitative Autistic Traits in Patients with Neurofibromatosis Type I. J Pediatr. 2015;167(3):621-6.e1. PMCID:PMC4792262  PMID:26051969 
73. Abadin SS, Zoellner NL, Schaeffer M, Porcelli B, Gutmann DH, Johnson KJ. Racial/Ethnic Differences in Pediatric Brain Tumor Diagnoses in Patients with Neurofibromatosis Type 1. J Pediatr. 2015;167(3):613-20.e1-2. PMCID:PMC4784699  PMID:26028287 
74. Chen YH, Gianino SM, Gutmann DH. Neurofibromatosis-1 regulation of neural stem cell proliferation and multilineage differentiation operates through distinct RAS effector pathways. Genes Dev. 2015;29(16):1677-82. PMCID:PMC4561477  PMID:26272820 
75. Anastasaki C, Woo AS, Messiaen LM, Gutmann DH. Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning. Hum Mol Genet. 2015;24(12):3518-28. PMCID:PMC4553714  PMID:25788518 
76. Bender RH, Haigis KM, Gutmann DH. Activated k-ras, but not h-ras or N-ras, regulates brain neural stem cell proliferation in a raf/rb-dependent manner. Stem Cells. 2015;33(6):1998-2010. PMCID:PMC4889217  PMID:25788415 
77. Liu Q, Zoellner N, Gutmann DH, Johnson KJ. Parental age and Neurofibromatosis Type 1: a report from the NF1 Patient Registry Initiative. Fam Cancer. 2015;14(2):317-24. PMID:25523354 
78. Kaul A, Toonen JA, Cimino PJ, Gianino SM, Gutmann DH. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth. Neuro Oncol. 2015;17(6):843-53. PMCID:PMC4483119  PMID:25534823 
79. Kaul A, Toonen JA, Gianino SM, Gutmann DH. The impact of coexisting genetic mutations on murine optic glioma biology. Neuro Oncol. 2015;17(5):670-7. PMCID:PMC4482850  PMID:25246427 
80. Brossier NM, Gutmann DH. Improving outcomes for neurofibromatosis 1-associated brain tumors. Expert Rev Anticancer Ther. 2015;15(4):415-23. PMID:25652347 
81. Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, Perentesis J, Schorry E, Ullrich N, Gutmann DH, Tonsgard J, Viskochil D, Korf B, Packer RJ, Fisher MJ. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015;17(4):596-603. PMCID:PMC4483073  PMID:25314964 
82. Solga AC, Pong WW, Walker J, Wylie T, Magrini V, Apicelli AJ, Griffith M, Griffith OL, Kohsaka S, Wu GF, Brody DL, Mardis ER, Gutmann DH. RNA-sequencing reveals oligodendrocyte and neuronal transcripts in microglia relevant to central nervous system disease. Glia. 2015;63(4):531-548. PMCID:PMC4331255  PMID:25258010 
83. Chen YH, McGowan LD, Cimino PJ, Dahiya S, Leonard JR, Lee DY, Gutmann DH. Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. Cell Rep. 2015;10(11):1899-912. PMCID:PMC4376586  PMID:25772366 
84. Soucy EA, Wessel LE, Gao F, Albers AC, Gutmann DH, Dunn CM. A pilot study for evaluation of hypotonia in children with neurofibromatosis type 1. J Child Neurol. 2015;30(3):382-5. PMCID:PMC4893773  PMID:24789516 
85. Pekmezci M, Reuss DE, Hirbe AC, Dahiya S, Gutmann DH, von Deimling A, Horvai AE, Perry A. Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Mod Pathol. 2015;28(2):187-200. PMID:25189642 
86. Pachow D, Wick W, Gutmann DH, Mawrin C. The mTOR signaling pathway as a treatment target for intracranial neoplasms. Neuro Oncol. 2015;17(2):189-99. PMCID:PMC4288522  PMID:25165193 
87. Ackerman SD, Garcia C, Piao X, Gutmann DH, Monk KR. The adhesion GPCR Gpr56 regulates oligodendrocyte development via interactions with Gα12/13 and RhoA. Nat Commun. 2015;6:6122. PMCID:PMC4302765  PMID:25607772 
88. Warrington NM, Sun T, Luo J, McKinstry RC, Parkin PC, Ganzhorn S, Spoljaric D, Albers AC, Merkelson A, Stewart DR, Stevenson DA, Viskochil D, Druley TE, Forys JT, Reilly KM, Fisher MJ, Tabori U, Allen JC, Schiffman JD, Gutmann DH, Rubin JB. The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients. Cancer Res. 2015;75(1):16-21. PMCID:PMC4286430  PMID:25381154 
89. Rauen KA, Huson SM, Burkitt-Wright E, Evans DG, Farschtschi S, Ferner RE, Gutmann DH, Hanemann CO, Kerr B, Legius E, Parada LF, Patton M, Peltonen J, Ratner N, Riccardi VM, van der Vaart T, Vikkula M, Viskochil DH, Zenker M, Upadhyaya M. Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues. Am J Med Genet A. 2015;167A(1):1-10. PMCID:PMC4275383  PMID:25393061 
90. Sharkey EK, Zoellner NL, Abadin S, Gutmann DH, Johnson KJ. Validity of participant-reported diagnoses in an online patient registry: a report from the NF1 Patient Registry Initiative. Contemp Clin Trials. 2015;40:212-7. PMID:25533730 
91. Madubata CC, Olsen MA, Stwalley DL, Gutmann DH, Johnson KJ. Neurofibromatosis type 1 and chronic neurological conditions in the United States: an administrative claims analysis. Genet Med. 2015;17(1):36-42. PMCID:PMC4257895  PMID:24901347 
92. Anastasaki C, Gutmann DH. Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation. Hum Mol Genet. 2014;23(25):6712-21. PMCID:PMC4245041  PMID:25070947 
93. Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, Parkinson DB, Stemmer-Rachamimov AO, Van Raamsdonk CD, Riccardi VM, Rosser T, Schindeler A, Smith MJ, Stevenson DA, Ullrich NJ, van der Vaart T, Weiss B, Widemann BC, Zhu Y, Bakker AC, Lloyd AC. Update from the 2013 International Neurofibromatosis Conference. Am J Med Genet A. 2014;164A(12):2969-78. PMCID:PMC4236251  PMID:25255738 
94. Schwetye KE, Gutmann DH. Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions. Expert Rev Neurother. 2014;14(10):1139-52. PMID:25161109 
95. Huang YC, Wei KC, Chang CN, Chen PY, Hsu PW, Chen CP, Lu CS, Wang HL, Gutmann DH, Yeh TH. Transglutaminase 2 expression is increased as a function of malignancy grade and negatively regulates cell growth in meningioma. PLoS One. 2014;9(9):e108228. PMCID:PMC4172767  PMID:25247996 
96. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834-43. PMID:25030515 
97. Gutmann DH. Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1. Neurology. 2014;83(5):463-71. PMCID:PMC4132567  PMID:24975854 
98. Johnson KJ, Mueller NL, Williams K, Gutmann DH. Evaluation of participant recruitment methods to a rare disease online registry. Am J Med Genet A. 2014;164A(7):1686-94. PMID:24700441 
99. Cabanski CR, Magrini V, Griffith M, Griffith OL, McGrath S, Zhang J, Walker J, Ly A, Demeter R, Fulton RS, Pong WW, Gutmann DH, Govindan R, Mardis ER, Maher CA. cDNA hybrid capture improves transcriptome analysis on low-input and archived samples. J Mol Diagn. 2014;16(4):440-51. PMCID:PMC4078367  PMID:24814956 
100. Kumar MG, Emnett RJ, Bayliss SJ, Gutmann DH. Glomus tumors in individuals with neurofibromatosis type 1. J Am Acad Dermatol. 2014;71(1):44-8. PMID:24685357 
101. Weiss B, Widemann BC, Wolters P, Dombi E, Vinks AA, Cantor A, Korf B, Perentesis J, Gutmann DH, Schorry E, Packer R, Fisher MJ. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer. 2014;61(6):982-6. PMID:24851266 
102. Garcia C, Gutmann DH. Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner. PLoS One. 2014;9(5):e97320. PMCID:PMC4016309  PMID:24817309 
103. Chen YH, Gutmann DH. The molecular and cell biology of pediatric low-grade gliomas. Oncogene. 2014;33(16):2019-26. PMID:23624918 
104. Gavilan HS, Kulikauskas RM, Gutmann DH, Fehon RG. In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila. PLoS One. 2014;9(3):e90853. PMCID:PMC3942481  PMID:24595234 
105. Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, Gutmann DH, Hanemann CO, Hennigan R, Huson S, Ingram D, Kissil J, Korf BR, Legius E, Packer RJ, McClatchey AI, McCormick F, North K, Pehrsson M, Plotkin SR, Ramesh V, Ratner N, Schirmer S, Sherman L, Schorry E, Stevenson D, Stewart DR, Ullrich N, Bakker AC, Morrison H. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A. 2014;164A(3):563-78. PMCID:PMC4150212  PMID:24443315 
106. Gomez GG, Volinia S, Croce CM, Zanca C, Li M, Emnett R, Gutmann DH, Brennan CW, Furnari FB, Cavenee WK. Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Res. 2014;74(5):1429-39. PMCID:PMC3947420  PMID:24436148 
107. Hirbe AC, Pekmezci M, Dahiya S, Apicelli AJ, Van Tine BA, Perry A, Gutmann DH. BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Neuro Oncol. 2014;16(3):466-7. PMCID:PMC3922521  PMID:24366910 
108. Diggs-Andrews KA, Brown JA, Gianino SM, Rubin JB, Wozniak DF, Gutmann DH. Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol. 2014;75(2):309-16. PMCID:PMC4172335  PMID:24375753 
109. Solga AC, Gianino SM, Gutmann DH. NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma. Oncogene. 2014;33(3):289-99. PMCID:PMC3874418  PMID:23318450 
110. Dahiya S, Emnett RJ, Haydon DH, Leonard JR, Phillips JJ, Perry A, Gutmann DH. BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol. 2014;16(2):318-9. PMCID:PMC3895374  PMID:24311634 
111. Garcia C, Gutmann DH. Using the neurofibromatosis tumor predisposition syndromes to understand normal nervous system development. Scientifica (Cairo). 2014;2014:915725. PMCID:PMC4163293  PMID:25243094 
112. Wessel LE, Gao F, Gutmann DH, Dunn CM. Longitudinal analysis of developmental delays in children with neurofibromatosis type 1. J Child Neurol. 2013;28(12):1689-93. PMID:23112244 
113. Wessel LE, Albers AC, Gutmann DH, Dunn CM. The association between hypotonia and brain tumors in children with neurofibromatosis type 1. J Child Neurol. 2013;28(12):1664-7. PMID:23071069 
114. Fisher MJ, Avery RA, Allen JC, Ardern-Holmes SL, Bilaniuk LT, Ferner RE, Gutmann DH, Listernick R, Martin S, Ullrich NJ, Liu GT, REiNS International Collaboration.. Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology. 2013;81(21 Suppl 1):S15-24. PMCID:PMC3908337  PMID:24249802 
115. Lin AL, Gutmann DH. Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol. 2013;10(11):616-24. PMID:23939548 
116. Licis AK, Vallorani A, Gao F, Chen C, Lenox J, Yamada KA, Duntley SP, Gutmann DH. Prevalence of Sleep Disturbances in Children With Neurofibromatosis Type 1. J Child Neurol. 2013;28(11):1400-1405. PMCID:PMC3805763  PMID:24065580 
117. Pong WW, Walker J, Wylie T, Magrini V, Luo J, Emnett RJ, Choi J, Cooper ML, Griffith M, Griffith OL, Rubin JB, Fuller GN, Piwnica-Worms D, Feng X, Hambardzumyan D, DiPersio JF, Mardis ER, Gutmann DH. F11R is a novel monocyte prognostic biomarker for malignant glioma. PLoS One. 2013;8(10):e77571. PMCID:PMC3795683  PMID:24147027 
118. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, TCGA Research Network.. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-77. PMCID:PMC3910500  PMID:24120142 
119. Ostendorf AP, Gutmann DH, Weisenberg JL. Epilepsy in individuals with neurofibromatosis type 1. Epilepsia. 2013;54(10):1810-4. PMID:24032542 
120. Kaul A, Chen YH, Emnett RJ, Gianino SM, Gutmann DH. Conditional KIAA1549:BRAF mice reveal brain region- and cell type-specific effects. Genesis. 2013;51(10):708-16. PMCID:PMC3808469  PMID:23893969 
121. Ji J, Shimony J, Gao F, McKinstry RC, Gutmann DH. Optic nerve tortuosity in children with neurofibromatosis type 1. Pediatr Radiol. 2013;43(10):1336-43. PMCID:PMC3904184  PMID:23636538 
122. Kliese N, Gobrecht P, Pachow D, Andrae N, Wilisch-Neumann A, Kirches E, Riek-Burchardt M, Angenstein F, Reifenberger G, Riemenschneider MJ, Meese E, Panayotova-Dimitrova D, Gutmann DH, Mawrin C. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene. 2013;32(39):4712-20. PMID:23108408 
123. Templer AK, Titus JB, Gutmann DH. A neuropsychological perspective on attention problems in neurofibromatosis type 1. J Atten Disord. 2013;17(6):489-96. PMID:22354384 
124. Wozniak DF, Diggs-Andrews KA, Conyers S, Yuede CM, Dearborn JT, Brown JA, Tokuda K, Izumi Y, Zorumski CF, Gutmann DH. Motivational disturbances and effects of L-dopa administration in neurofibromatosis-1 model mice. PLoS One. 2013;8(6):e66024. PMCID:PMC3677926  PMID:23762458 
125. Karasinska JM, de Haan W, Franciosi S, Ruddle P, Fan J, Kruit JK, Stukas S, Lütjohann D, Gutmann DH, Wellington CL, Hayden MR. ABCA1 influences neuroinflammation and neuronal death. Neurobiol Dis. 2013;54:445-55. PMID:23376685 
126. Hawasli AH, Rubin JB, Tran DD, Adkins DR, Waheed S, Hullar TE, Gutmann DH, Evans J, Leonard JR, Zipfel GJ, Chicoine MR. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base. 2013;74(3):136-41. PMCID:PMC3709924  PMID:24436903 
127. O'Brien DE, Brenner DS, Gutmann DH, Gereau RW 4th. Assessment of pain and itch behavior in a mouse model of neurofibromatosis type 1. J Pain. 2013;14(6):628-37. PMCID:PMC3672240  PMID:23578956 
128. Dahiya S, Haydon DH, Alvarado D, Gurnett CA, Gutmann DH, Leonard JR. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol. 2013;125(6):901-10. PMID:23609006 
129. Ostendorf AP, McKinstry RC, Shimony JS, Gutmann DH. Teaching NeuroImages: T2 hyperintensities in neurofibromatosis type 1. Neurology. 2013;80(20):e215-6. PMCID:PMC3908353  PMID:23671349 
130. Schulz A, Baader SL, Niwa-Kawakita M, Jung MJ, Bauer R, Garcia C, Zoch A, Schacke S, Hagel C, Mautner VF, Hanemann CO, Dun XP, Parkinson DB, Weis J, Schröder JM, Gutmann DH, Giovannini M, Morrison H. Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Nat Neurosci. 2013;16(4):426-33. PMID:23455610 
131. Gutmann DH, Blakeley JO, Korf BR, Packer RJ. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs. 2013;22(4):443-62. PMCID:PMC4009992  PMID:23425047 
132. Diggs-Andrews KA, Gutmann DH. Modeling cognitive dysfunction in neurofibromatosis-1. Trends Neurosci. 2013;36(4):237-47. PMCID:PMC3622809  PMID:23312374 
133. Johnson KJ, Hussain I, Williams K, Santens R, Mueller NL, Gutmann DH. Development of an international internet-based neurofibromatosis Type 1 patient registry. Contemp Clin Trials. 2013;34(2):305-11. PMID:23246715 
134. Soucy EA, van Oppen D, Nejedly NL, Gao F, Gutmann DH, Hollander AS. Height assessments in children with neurofibromatosis type 1. J Child Neurol. 2013;28(3):303-7. PMCID:PMC3947790  PMID:22752476 
135. Gutmann DH, McLellan MD, Hussain I, Wallis JW, Fulton LL, Fulton RS, Magrini V, Demeter R, Wylie T, Kandoth C, Leonard JR, Guha A, Miller CA, Ding L, Mardis ER. Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res. 2013;23(3):431-9. PMCID:PMC3589532  PMID:23222849 
136. Diggs-Andrews KA, Tokuda K, Izumi Y, Zorumski CF, Wozniak DF, Gutmann DH. Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. Ann Neurol. 2013;73(2):309-15. PMCID:PMC3608728  PMID:23225063 
137. Pong WW, Higer SB, Gianino SM, Emnett RJ, Gutmann DH. Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. Ann Neurol. 2013;73(2):303-8. PMCID:PMC3608848  PMID:23424002 
138. Gutmann DH, Avery R, Ferner RE, Listernick R. Visual function and optic pathway glioma: a critical response. JAMA Ophthalmol. 2013;131(1):120-1. PMID:23307228 
139. Isenberg JC, Templer A, Gao F, Titus JB, Gutmann DH. Attention skills in children with neurofibromatosis type 1. J Child Neurol. 2013;28(1):45-9. PMID:22496119 
140. Ho CY, Bar E, Giannini C, Marchionni L, Karajannis MA, Zagzag D, Gutmann DH, Eberhart CG, Rodriguez FJ. MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2. Neuro Oncol. 2013;15(1):69-82. PMCID:PMC3534421  PMID:23161775 
141. Kaul A, Chen YH, Emnett RJ, Dahiya S, Gutmann DH. Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes Dev. 2012;26(23):2561-6. PMCID:PMC3521628  PMID:23152448 
142. Johnson KJ, Fisher MJ, Listernick RL, North KN, Schorry EK, Viskochil D, Weinstein M, Rubin JB, Gutmann DH. Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas. Fam Cancer. 2012;11(4):653-6. PMCID:PMC3693850  PMID:22829012 
143. Gutmann DH, Parada LF, Silva AJ, Ratner N. Neurofibromatosis type 1: modeling CNS dysfunction. J Neurosci. 2012;32(41):14087-93. PMCID:PMC3477849  PMID:23055477 
144. Avery RA, Ferner RE, Listernick R, Fisher MJ, Gutmann DH, Liu GT. Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J Neurooncol. 2012;110(1):1-7. PMID:22843451 
145. Camargo N, Brouwers JF, Loos M, Gutmann DH, Smit AB, Verheijen MH. High-fat diet ameliorates neurological deficits caused by defective astrocyte lipid metabolism. FASEB J. 2012;26(10):4302-15. PMID:22751013 
146. Acosta MT, Bearden CE, Castellanos FX, Cutting L, Elgersma Y, Gioia G, Gutmann DH, Lee YS, Legius E, Muenke M, North K, Parada LF, Ratner N, Hunter-Schaedle K, Silva AJ. The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. Am J Med Genet A. 2012;158A(9):2225-32. PMCID:PMC4074877  PMID:22821737 
147. Lee DY, Gianino SM, Gutmann DH. Innate neural stem cell heterogeneity determines the patterning of glioma formation in children. Cancer Cell. 2012;22(1):131-8. PMCID:PMC3396885  PMID:22789544 
148. Tien AC, Tsai HH, Molofsky AV, McMahon M, Foo LC, Kaul A, Dougherty JD, Heintz N, Gutmann DH, Barres BA, Rowitch DH. Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord. Development. 2012;139(14):2477-87. PMCID:PMC3383225  PMID:22675209